The PTCOG 2020 Online Meeting boasts 6 individual keynote sessions from the following leading experts:
“Taking Care with FLASH Radiotherapy”
Jolyon Hendry, PhD, DSc
4pm – 4:45pm Sunday 13 September, Central European Summer Time (GMT+2)
Jolyon Hendry is a Radiation Biologist at the Paterson Institute for Cancer Research, Christie Hospital, Manchester UK, for 30 years. FLASH experiments in vivo 1982. Emeritus Honorary Professor at Manchester University and the Chinese Academy of Medical Sciences. Chief Editor of the International Journal of Radiation Biology for 7 years. Past chairman of the LH Gray Memorial Trust and the Association for Radiation Research. Head of the Applied Radiobiology and Radiotherapy Section, International Atomic Energy Agency, Vienna for the last of 5 years. Secretary of Committee 1 of the International Commission on Radiological Protection. Director of the MSc course in Radiation Biology, Churchill Hospital, University of Oxford. Recipient of the Roentgen Prize from the British Institute of Radiology, the Weiss Medal from the Association for Radiation Research UK, and the Bacq and Alexander Award from the European Radiation Research Society.
“Economic Accessibility of Proton and Particle Therapy”
Rock Mackie, PhD
5pm – 5:45pm Sunday 13 September, Central European Summer Time (GMT+2)
“Rock” Mackie has a BSc in Physics (1980) from the University of Saskatchewan and a PhD in Physics (1984) from the University of Alberta. In 1987 he left Canada and came to the University of Wisconsin-Madison and became a full professor in 1998 in the Department of Medical Physics while practicing as a clinical medical physicist and conducting radiotherapy physics research in the Department of Human Oncology. He was at the UW for 25 years and supervised more than 40 PhD students and co-authored more than 180 peer-reviewed publications. He also had an appointment in Engineering Physics with the UW College of Engineering and was a faculty affiliate in the Department of Biomedical Engineering in the same college. He has been a UW Professor Emeritus since 2012 and an Emeritus Investigator at the Morgridge Institute for Research since 2015. He has been awarded the Coolidge Gold Medal from the AAPM (2014), the Gold Medal from ASTRO (2019) and the John Mallard Award for Innovation from the IOMP (2019).
Rock Mackie has a long entrepreneurial career both as an academic and since retiring as a professor. He is the founding Chief Innovation Officer of UW Health and the Chairman of the Board of the Isthmus Project, a UW Health innovation incubator program. He is a co-founder and Chairman of the Board for the Center for the Assessment of Radiological Sciences (CARS), a not-for-profit organization supporting quality in radiation oncology and radiology. In 1992 he co-founded Geometrics Corporation to develop the Pinnacle radiotherapy treatment planning system, which originated from his clinical and research work. Now owned by Philips Medical Corporation, it was once the largest selling radiation therapy treatment planning system in the world. In 1997, Rock co-founded TomoTherapy in 1997, an image-guided intensity modulated radiotherapy company and was its Chairman of the Board from founding to IPO and on to sale to Accuray Corporation in 2011. He is an investor and founding board member of several medical companies including HealthMyne, Asto CT, Leo Cancer Care, Shine Medical Technologies, and OnLume. He is an investor in several medical companies including Elucent, IMVD, Image Mover, TAI Diagnostics, Cellectar, Redox, Oncora and Stemina. He also serves on the boards or advises several other non-medical companies including BioIonix, Linectra, and SmartUQ.
“Proton Therapy for Head and Neck Cancer: Practical Applications of Proton Therapy for Head and Neck Cancer Past, Present, and the Future”
Nancy Lee, MD
6pm – 6:45pm Sunday 13 September, Central European Summer Time (GMT+2)
As the Service Chief of Proton Therapy at the Memorial Sloan-Kettering Cancer Center (MSKCC), Nancy Y Lee, MD, FASTRO, has been treating head and neck cancer patients using proton therapy since 2013. She is the lead editor of a top selling book, “Target Volume Delineation and Treatment Planning for Particle Therapy: A Practical Guide.” As both the Vice Chairman of Experimental Therapeutics and Director of Head and Neck Cancer at MSKCC, her goal is to generate evidence-based application of proton therapy for head and neck cancer as well taking proton therapy to the next level, beyond simply treating patients with this technology. Her goal and passion are to bridge the gap of physical science, i.e., technologic advances with biologic advances, i.e. immunotherapy. She will also focus on developing FLASH proton therapy with goal of further toxicity reduction, deciphering its mechanism where she leads the MSKCC FLASH radiotherapy team working in conjunction with the New York Proton Center FLASH Consortium. She is also the PI for several NRG Oncology trials that applies proton therapy for various head and neck cancer and is the PI of several investigator-initiated trials that will generate further evidence that demonstrates the value of proton therapy for head and neck cancer. Dr. Lee has authored and co-authored numerous scientific papers and review articles on the implementation of proton therapy for head and neck cancer. She brings a wealth of experience from treating patients at both Procure, NJ as well as the New York Proton Center.
“Carbon Ion Irradiation with Immune Checkpoint Blockade for Osteosarcoma”
Yutaka Takahashi PhD
1pm – 1:45pm Monday 14 September, Central European Summer Time (GMT+2)
Yutaka Takahashi PhD completed both a master and PhD at the Osaka University Graduate School of Medicine in the Department of Medical Engineering and the Department of Medical Physics and Engineering, respectively. During and following his studies Takahashi was also a researcher and medical physicist for 5 years in Division of Physics, Japanese Foundation for Cancer Research, Tokyo, Japan. He then held a 4-year position as an Assistant Professor in the Department of Radiation Oncology in Osaka University Graduate School of Medicine, Osaka Japan, before a 3-year postdoctoral associate position in the Masonic Cancer Center in University of Minnesota, USA. Since his return to Japan, Takahashi has held an Assistant Professor position in the Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka Japan.
“Setting up a State-of-the-Art Proton Therapy Facility in India: Journey and Preliminary Experience”
Dr Rakesh Jalali
2pm – 2:45pm Monday 14 September, Central European Summer Time (GMT+2)
Dr Rakesh Jalali is providing clinical and administrative leadership to India’s and South Asia’s first proton therapy facility and state-of-the art advanced cancer centre, the Apollo Proton Cancer Centre (APCC) attached to it. He has been closely involved in the set up and growth of the proton facility and is a key opinion leader in the field in the region.
Before joining Apollo, Dr. Jalali spent 18 long fruitful years at Tata Memorial Hospital, Mumbai where he led the Neuro Oncology Group as the finest such unit in India. His research interests and publications over the years have focused on generating quality evidence for modern high-precision radiotherapy and minimizing several patient reported outcome measures and quality of life issues in neuro oncology practice in the region along with novel insights in long-term cancer survivorship. He was also instrumental in establishing the Indian Society of Neuro-Oncology (ISNO) in 2008 serving as its founding general secretary, then its President and now chairing its senior advisory council. Dr. Jalali and his team have published extensively including in high-impact journals such as the Lancet, Lancet Oncology, JAMA Oncology, JCO, etc, some having helped guide treatment philosophies in the management of cancers. A much sought-after speaker, he is widely regarded for his teaching and providing expert guidance to various national and international scientific meetings and professional societies.
He is also closely involved in Brain Tumour Foundation of India, a charity dedicated to the welfare of brain tumour patients and their families.
“Applications of Artificial Intelligence in Particle Therapy”
Dr Steve Jiang
3pm – 3:45pm Monday 14 September, Central European Summer Time (GMT+2)
Dr. Steve Jiang received his Ph.D. in Medical Physics from Medical College of Ohio in 1998. After completing his postdoctoral training at Stanford University, he joined Massachusetts General Hospital and Harvard Medical School in 2000 as an Assistant Professor of Radiation Oncology. In 2007, Dr. Jiang was recruited to University of California San Diego as a tenured Associate Professor to build Center for Advanced Radiotherapy Technologies, for which he was the founding and executive director. He was then promoted to Full Professor with tenure in 2011. In October 2013, Dr. Jiang joined University of Texas Southwestern Medical Center as a tenured Full Professor, Barbara Crittenden Professor in Cancer Research, Vice Chair of Radiation Oncology Department, and Director of Medical Physics and Engineering Division. Dr. Jiang is a Fellow of Institute of Physics and American Association of Physicists in Medicine. Dr. Jiang’s research in various areas of cancer radiotherapy has been funded by federal, state, charitable, and industrial grants for over 15 million dollars, resulting in over 190 peer-reviewed journal papers with an H-index of 72. His current research interest is on the development and deployment of artificial intelligence technologies to solve medical problems. He is the founding director for both Medical Artificial Intelligence and Automation Laboratory and Program of Excellence in Intelligent Medicine at UT Southwestern. He has supervised over 30 postdoctoral fellows and 10 Ph.D. students.